Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study

@inproceedings{Fuse2016AdjuvantCP,
  title={Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study},
  author={Nozomu Fuse and Hideaki Bando and Keisho Ch{\`i}n and Seiji Ito and Takaki Yoshikawa and Akira Tsuburaya and Masanori Terashima and Yoshiyuki Kawashima and Tetsu Fukunaga and Masahiro Gotoh and Yasunori Emi and Kazuhiro Yoshida and Eiji Oki and Seiji Takahashi and Hiroshi Kuriki and Kumi Sato and Mitsuru Sasako},
  booktitle={Gastric Cancer},
  year={2016}
}
Adjuvant chemotherapy with XELOX (capecitabine plus oxaliplatin) has been shown to be beneficial following resection of gastric cancer in South Korean, Chinese, and Taiwanese patients. This phase II study (J-CLASSIC-PII) was undertaken to evaluate the feasibility of XELOX in Japanese patients with resected gastric cancer. Patients with stage II or III gastric cancer who underwent curative D2 gastrectomy received adjuvant XELOX (eight 3-week cycles of oral capecitabine, 1000 mg/m2 twice daily on… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
10 Citations
16 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Similar Papers

Loading similar papers…